Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and ...
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, founded in 2018. The company is dedicated to addressing significant unmet medical needs in viral and liver diseases through the development of novel therapeutics. Its pipeline includes several drug candidates at various stages of ...Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, founded in 2018. The company is dedicated to addressing significant unmet medical needs in viral and liver diseases through the development of novel therapeutics. Its pipeline includes several drug candidates at various stages of clinical development. For chronic hepatitis B (CHB), Aligos is advancing ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer in Phase Ib trials; ALG-000184, a capsid assembly modulator in Phase I trials; ALG-020572, an antisense oligonucleotide targeting HBsAg translation and secretion; and multiple siRNA candidates including ALG-125755, ALG-125097, and ALG-125819, which inhibit HBsAg release from infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a THR-β agonist in Phase 1a/1b studies. Additionally, Aligos has formed strategic alliances with Luxna Biotech (HBV oligonucleotide licensing), Emory University (capsid assembly modulator technology), Katholieke Universiteit Leuven (coronavirus protease inhibitors), and Merck (NASH oligonucleotide research). As of the latest data, the company has 82 full-time employees and a market capitalization of approximately $45 million. Financially, Aligos reports negative net income and operating cash flows, reflecting its clinical-stage status and heavy R&D expenditure. The company's key leadership includes CEO Lawrence Blatt, Ph.D., a co-founder with extensive biotechnology experience. Overall, Aligos aims to become a world leader in antiviral and liver disease therapeutics, leveraging its innovative science and strategic partnerships.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$2.2M
-44.6%
+881.6%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-24.2M
+81.6%
+93.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+57.5%
-42.5%
0.0%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-4024.9%
-78.1%
+99.3%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-1106.7%
+66.7%
+99.3%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-82.9M
-2.6%
-7.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-3794.1%
-85.1%
+89.0%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
9.8%
+133.9%
-19.7%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
3.90x
+36.5%
-14.3%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
